by Plus Therapeutics | Nov 15, 2024 | GBM
Plus Therapeutics at the ABTA Race in New York: Supporting Brain Cancer Awareness and Education Check out this photo of our dedicated patient advocacy team at the @the_ABTA race in New York last weekend! The Plus Therapeutics team was proud to support and participate...
by Plus Therapeutics | Nov 15, 2024 | Uncategorized
ICYMI: Watch the Plus Therapeutics Q3 2024 Conference Call Webcast Replay Catch up on the latest financial results and updates from Plus Therapeutics! If you missed yesterday’s conference call, don’t worry – you can still access the webcast replay to hear...
by Plus Therapeutics | Nov 9, 2024 | Uncategorized
Join Plus Therapeutics at the Upcoming 5K Event in New York! Meet Our Patient Advocacy Team Speaking about ReSPECT-GBM and Recurrent Glioblastoma Don’t miss the chance to visit the Plus Therapeutics booth at the ABTA NYC community 5K next week in New York! We’re...
by Plus Therapeutics | Nov 8, 2024 | LM
You’re Invited: Symposium on Novel Targeted Radiotherapies for Leptomeningeal Metastases at the 2025 Society for Neuro-Oncology Annual Meeting in Houston Join Us at the SNO Annual Conference to Explore Groundbreaking Advances in Leptomeningeal Metastasis...
by Plus Therapeutics | Nov 6, 2024 | Uncategorized
BREAKING NEWS: Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain redundancy Press...
Recent Comments